NCT02275338

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

An International, Multicentric, Prospective, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 MG Associated to Standard of Care in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Ipsen · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To assess the efficacy of Lanreotide Autogel 120 mg for the relief of vomiting due to inoperable malignant intestinal obstruction in patients without nasogastric tube (NGT) and to assess the efficacy of lanreotide Autogel 120 mg on removal of nasogastric tube without the recurrence of vomiting in patients with an inoperable malignant intestinal obstruction with a nasogastric tube.

Conditions

• Intestinal Obstruction

Interventions

Type	Name	Description
DRUG	Lanreotide Autogel	120mg administered via deep subcutaneous injection at Day 0 and Day 28.

Timeline

• Start date: 2014-11-19
• Primary completion: 2017-11-09
• Completion: 2017-11-09
• First posted: 2014-10-27
• Last updated: 2019-04-16
• Results posted: 2019-04-01

Locations

17 sites across 1 country: Belgium